Doctor

Only available on StudyMode
  • Download(s) : 30
  • Published : April 4, 2013
Open Document
Text Preview
2011

Pfizer’s Centers for Therapeutic Innovation By Dr. Minna Allarakhia Editor, CanBiotech Inc. Director, BioEndeavor Network

April 2011 @CanBiotech Inc.

2011

Open Innovation Case Study: Pfizer’s Centers for Therapeutic Innovation

Pfizer’s Centers for Therapeutic Innovation
By Dr. Minna Allarakhia Editor, CanBiotech Inc. Director, BioEndeavor Network

Abstract Pfizer recently announced the formation of a network of academic collaborators to accelerate the translation of basic science into biologics-based drugs. Pfizer anticipates establishing local Centers at each partner site enabling Pfizer and Academic Medical Center teams to work closely together. The University of California, San Francisco (UCSF), has signed on as the first of multiple partners. The partnerships will follow a venture capital-funded biotechnology start-up model, whereby Pfizer funds preclinical and clinical development programs and offers equitable intellectual property and ownership rights. Pfizer has the goal of expanding the Centers to Europe and Asia in 2012. Assuming eight projects per CTI, this could bring dozens of differentiated entities against targets into Pfizer’s pipeline. 1.0 Introduction Pfizer recently announced the formation of a network of academic collaborators to accelerate the translation of basic science into biologics-based drugs. According to Mikael Dolsten, M.D., Ph.D., president of Pfizer Worldwide Research & Development, the Centers represents a novel open innovation paradigm, combining the competencies of top academic research institutions with Pfizer's leading drug development capabilities and research technologies. (Pfizer, 2010) The Centers for Therapeutic Innovation (CTI) will initially focus on collaborations within the U.S. Pfizer expects to expand into Europe and Asia in 2012. Each Center will be governed by a Joint Steering Committee (JSC)

comprised of Pfizer and Academic Medical Center (AMC) representatives who will provide leadership and evaluate the success of each program through discovery and early stage clinical development. Through this innovation model, Pfizer will have the opportunity to broaden its pipeline with novel candidate drugs to treat diseases—addressing unmet medical need. (Pfizer, 2010) 2.0 The Partners The University of California, San Francisco (UCSF), has signed on as the first of multiple partners in Pfizer’s Global Centers for Therapeutic Innovation. UCSF will receive up to $85 million in research support and milestone payments over the course of the five-year partnership. Pfizer will open labs adjacent to the UCSF campus, where Pfizer scientists will work alongside university researchers to find new biologics targeting a range of diseases. Although Pfizer has an R&D site in South San Francisco, proximity to the UCSF campus is seen as critical to fostering an effective intellectual exchange according to Anthony J. Coyle, who will head CTI. (Jarvis, 2010) In January of 2011, Pfizer Inc. further announced that seven major research-based medical centers in New York City joined Pfizer’s CTI. The New York medical centers include: Rockefeller University, New York University Langone Medical Center, Memorial Sloan-Kettering Cancer Center, The Mount Sinai Medical Center, Columbia University Medical Center, Albert Einstein College of Medicine of Yeshiva University, and Weill Cornell Medical College. Pfizer has signed a lease at the Alexandria Center for Life Science—providing the company with research space to facilitate its New York Citybased collaborations. The Alexandria Center is a life science park in New York City and home to a number of research organizations and leading life science entities. Its office and laboratory space encourages collaboration and Page 2

©CanBiotech Inc. 2011 Pfizer’s Centers for Therapeutic Innovation

2011

Open Innovation Case Study: Pfizer’s Centers for Therapeutic Innovation

is ideally located to facilitate close working relationships...
tracking img